Trial reportArchives of gynecology and obstetrics2022
Effect of metformin and exenatide on pregnancy rate and pregnancy outcomes in overweight or obese infertility PCOS women: long-term follow-up of an RCT.
Trial report in Archives of gynecology and obstetrics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05702905 (Semaglutide Improves Metabolic Abnormalities and Fertility in Obese Infertile Women With Polycystic Ovary Syndrome), which is not on this map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Semaglutide Improves Metabolic Abnormalities and Fertility in Obese Infertile Women With Polycystic Ovary Syndrome: a Prospective, Randomized, Open, Controlled Study
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials.Scientific reports · 2025Pooled it
- Comparison of exenatide alone or combined with metformin versus metformin in the treatment of polycystic ovaries: a systematic review and meta-analysis.BMC endocrine disorders · 2023Pooled it
- Effects of GLP1RAs on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic review.BMC endocrine disorders · 2023 · on this mapPooled it
- Effects of Ziziphus jujuba, metformin, and myoinositol on pregnancy rates and metabolic parameters in infertile women with PCOS: a randomized controlled trial.Journal of ovarian research · 2026Trial
- Mitochondrial Function and Dysfunction in Female Fertility: Biological Mechanisms, Genetic Determinants, and Therapeutic Opportunities - A Review.Reproductive sciences (Thousand Oaks, Calif.) · 2026Review
- Periconceptional use of GLP-1 receptor agonists and the risk of major congenital malformations: a systematic review and meta-analysis.Endocrine connections · 2026Article
- GLP-1 Receptor Agonists in Reproductive Medicine: A Narrative Review and Investigational Pilot Survey of Patient Perspectives in Academic Reproductive Endocrinology.Reproductive sciences (Thousand Oaks, Calif.) · 2026Review
- The Double-Edged Sword of Gestational Insulin Resistance: Navigating Maternal Adaptation and Its Risks for Pregnancy and Offspring Health.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026Review
- The efficacy and safety of novel antidiabetic agents in polycystic ovary syndrome: a network meta-analysis.Journal of ovarian research · 2026Article
- Weight management in women of reproductive age.Obesity and endocrinology · 2026Review
- Balancing metabolic optimization and reproductive safety in Polycystic Ovary Syndrome: a Bayesian-informed framework for GLP-1 receptor agonists.Frontiers in nutrition · 2026Review
- The Expanding Scope of GLP-1 Receptor Agonists: Six Uses Beyond Diabetes.Current atherosclerosis reports · 2025Review
- Metformin use in women with polycystic ovary syndrome (PCOS): Opportunities, benefits, and clinical challenges.Diabetes, obesity & metabolism · 2025Review
- Endocrine and metabolic effects of GLP-1 receptor agonists on women with PCOS, a narrative review.Endocrine connections · 2025Review
- GLP-1 receptor agonist for weight loss and fertility: Social media and online perception versus evidence-based medicine.PloS one · 2025Review
- Incretin Hormone Secretion in Women with Polycystic Ovary Syndrome: Roles of Obesity, Insulin Sensitivity and Treatment with Metformin and GLP-1s.Biomedicines · 2024Review
- Infertility Improvement after Medical Weight Loss in Women and Men: A Review of the Literature.International journal of molecular sciences · 2024 · on this mapReview
- RNA editing landscape of adipose tissue in polycystic ovary syndrome provides insight into the obesity-related immune responses.Frontiers in endocrinology · 2024Article
- Depression score mediate the association between a body shape index and infertility in overweight and obesity females, NHANES 2013-2018.BMC women's health · 2023Article
- Clinical analysis of 78 patients with nonclassical 21-hydroxylase deficiency.Archives of gynecology and obstetrics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe majority of Polycystic ovary syndrome (PCOS) are overweight or obese with increased infertility and high risk of pregnancy complications. We aim to compare efficacy of metformin and exenatide on spontaneous pregnancy rate, overall pregnancy rate after assisted reproductive technology treatment (ART) and pregnancy outcomes in overweight or obese infertility PCOS.
methodsIn this long-term follow-up study, 160 overweight or obese infertility Chinese PCOS were randomized to exenatide or metformin treatment for 12 weeks. Afterward, all were treated with metformin alone until pregnancy confirmed and followed until delivery. If patients failed spontaneous pregnancy during the second 12 weeks, ART could be offered until end of 64 weeks. The primary outcome was spontaneous pregnancy rate.
resultsAt week 24, 29.2% of women in exenatide group conceived spontaneously while 14.7% in metformin group (p = 0.03). At week 64, total pregnancy rates were 79.2% in exenatide group and 76% in metformin group without significant difference (p = 0.65). Between two groups, there was no significant difference of pregnancy outcomes (p > 0.05). A stepwise logistic regression showed that spontaneous pregnancy was positively associated with body weight reduction and HOMA-IR improvement in either group.
conclusionIn overweight or obese infertility Chinese PCOS, 12 weeks pregestational exenatide treatment resulted in more spontaneous pregnancy likely due to greater weight reduction and improvement of insulin resistance compared with metformin treatment without obvious benefit on overall pregnancy rate after ART or pregnancy outcomes of successful conceived women.
trial registrationThis clinical trial was registered at Chinese Clinical Trials Registry (ChiCTR-IIR-16008084) on 13/3/2016.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.